Northland

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. Established in June 2004, the company was among the first batch of enterprises listed on the Beijing Stock Exchange, with the stock code 430047. It is a key national high-tech enterprise under the Torch Plan, a Beijing-based research and development institution, the Beijing Engineering Research Center for Plasmid-based Gene Therapy Drugs, an international science and technology cooperation base in Beijing, a G20 innovation-leading enterprise in Beijing’s biopharmaceutical industry, and a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Beijing.The company boasts a highly qualified R&D and management team, accumulating extensive experience in preclinical research, clinical research, production and quality management, pharmaceutical plant construction, and drug operation. It has established core technology platforms such as gene vector construction, engineering bacteria construction, microbial expression, mammalian cell expression, biologics production processes, large-scale production technologies, and eyedrop drug development, providing a solid foundation for continuous project development. Guided by clinical needs and relying on its proprietary core technology platforms, the company primarily focuses on the research and industrialization of bioengineered new drugs in areas such as cardiovascular diseases, metabolic diseases, rare diseases, and ophthalmic diseases.